Ceryx Medical has initiated the first-in-human study of its Cysoni™ RSA Pacemaker’s potential to provide superior treatment for heart failure patients by boosting cardiac output through Respiratory Sinus Arrhythmia (RSA) inputs.
According to the company’s announcement today, the first human patient has been enrolled for the RSA-Pace study at Waikato Hospital in Hamilton, New Zealand. The record-setting study focuses on evaluating the company’s technology in heart failure patients requiring temporary pacing after surgery.
RSA is a natural synchronization of the lungs and heart rhythms, which usually helps maximize cardiac output and efficiency. However, in patients suffering from heart failure, this critical synchrony is mostly non-existent, necessitating the need for temporary pacing to restore the natural synchronized rhythm. And that’s where Ceryx’s Cysoni pacing technology comes in.
According to Ceryx Medical, the pacing technology has proven to boost cardiac output significantly by about 20% and minimize common symptoms of heart failure, such as apnoeas, based on an in-vivo study. The technology can also be used alongside other available therapies to improve patient outcomes.
Dr Stuart Plant, CEO of Ceryx, stated that his team is optimistic that the result from the first inhuman study, which will enroll 60 patients in the UK, Australia, and New Zealand, will be critical in developing temporary and permanent pacing devices based on the novel approach.
Expressing his optimism about the study and its future implications, Dr Martin Stiles, the principal investigator at Waikato Hospital, stated that the technology has the potential to boost cardiac output than the already existing pacing technologies.
